Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2002 May;48:905–912.

St John's wort or sertraline? Randomized controlled trial in primary care.

Gerald van Gurp 1, Greg B Meterissian 1, Laura N Haiek 1, Jane McCusker 1, François Bellavance 1
PMCID: PMC2214056  PMID: 12053635

Abstract

OBJECTIVE: To compare the change in severity of depressive symptoms and occurrence of side effects in primary care patients treated with St John's wort (SJW) and sertraline. DESIGN: Double-blind, randomized 12-week trial. SETTING: Community-based offices of 12 family physicians practising in greater Montreal, Que. PARTICIPANTS: Eighty-seven men and women with major depression and an initial score of > or = 16 on the Hamilton Rating Scale for Depression (Ham-D). INTERVENTIONS: Patients were randomized to treatment with either sertraline (50 to 100 mg/d) or SJW (900 to 1800 mg/d) in a double-blind fashion. Assessment of depression was done at entry and at 2, 4, 8, and 12 weeks using the Ham-D, the Beck Depression Inventory (BDI), and a questionnaire asking about compliance and side effects. MAIN OUTCOME MEASURES: Changes from baseline in Ham-D and BDI scores and self-reported side effects. RESULTS: There were no important differences in changes in mean Ham-D and BDI scores (using intention-to-treat analysis), with and without adjustment for baseline demographic characteristics, between the two groups at 12 weeks. Significantly more side effects were reported in the sertraline group than in the SJW group at 2 and 4 weeks' follow up. CONCLUSION: The more benign side effects of SJW make it a good first choice for this patient population.

Full Text

The Full Text of this article is available as a PDF (291.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BECK A. T., WARD C. H., MENDELSON M., MOCK J., ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
  2. Brenner R., Azbel V., Madhusoodanan S., Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther. 2000 Apr;22(4):411–419. doi: 10.1016/S0149-2918(00)89010-4. [DOI] [PubMed] [Google Scholar]
  3. De Smet P. A., Nolen W. A. St John's wort as an antidepressant. BMJ. 1996 Aug 3;313(7052):241–242. doi: 10.1136/bmj.313.7052.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Greene W. L., Concato J., Feinstein A. R. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med. 2000 May 2;132(9):715–722. doi: 10.7326/0003-4819-132-9-200005020-00006. [DOI] [PubMed] [Google Scholar]
  5. Hamilton M. Rating depressive patients. J Clin Psychiatry. 1980 Dec;41(12 Pt 2):21–24. [PubMed] [Google Scholar]
  6. Linde K., Ramirez G., Mulrow C. D., Pauls A., Weidenhammer W., Melchart D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. BMJ. 1996 Aug 3;313(7052):253–258. doi: 10.1136/bmj.313.7052.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. McCusker J., Cole M., Keller E., Bellavance F., Berard A. Effectiveness of treatments of depression in older ambulatory patients. Arch Intern Med. 1998 Apr 13;158(7):705–712. doi: 10.1001/archinte.158.7.705. [DOI] [PubMed] [Google Scholar]
  8. Moses E. L., Mallinger A. G. St. John's Wort: three cases of possible mania induction. J Clin Psychopharmacol. 2000 Feb;20(1):115–117. doi: 10.1097/00004714-200002000-00027. [DOI] [PubMed] [Google Scholar]
  9. Nierenberg A. A., Burt T., Matthews J., Weiss A. P. Mania associated with St. John's wort. Biol Psychiatry. 1999 Dec 15;46(12):1707–1708. doi: 10.1016/s0006-3223(99)00233-4. [DOI] [PubMed] [Google Scholar]
  10. Philipp M., Kohnen R., Hiller K. O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ. 1999 Dec 11;319(7224):1534–1538. doi: 10.1136/bmj.319.7224.1534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000 Mar;15(2):61–68. doi: 10.1097/00004850-200015020-00001. [DOI] [PubMed] [Google Scholar]
  12. Shelton R. C., Keller M. B., Gelenberg A., Dunner D. L., Hirschfeld R., Thase M. E., Russell J., Lydiard R. B., Crits-Cristoph P., Gallop R. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001 Apr 18;285(15):1978–1986. doi: 10.1001/jama.285.15.1978. [DOI] [PubMed] [Google Scholar]
  13. Snow V., Lascher S., Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 2000 May 2;132(9):738–742. doi: 10.7326/0003-4819-132-9-200005020-00010. [DOI] [PubMed] [Google Scholar]
  14. Vorbach E. U., Arnoldt K. H., Hübner W. D. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997 Sep;30 (Suppl 2):81–85. doi: 10.1055/s-2007-979524. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES